Eli Lilly Poised to Nab First to Market Advantage with its IL-23 Inhibitor Mirikizumab in Ulcerative Colitis, Creating an Opportunity to Build a Loyal Base Ahead of AbbVie and Janssen’s Respective IL-23 Entries, According to Spherix Global Insights

Gastroenterologists project mirikizumab will play a significant role in the treatment of ulcerative colitis EXTON, Pa., March 24, 2023 /PRNewswire/ — In 2021, Eli Lilly (“Lilly”) announced it would forego pursuing a psoriasis indication for its IL-23 inhibitor mirikizumab, strategically…